drugset / Trial / NCT04946929
Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)
RandomizedParallel-groupOpen-labelTreatment
Summary
Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor with faster onset of action and greater platelet inhibition) was used to treat patients with pediatric post-transplant hepatic artery thrombosis (HAT) compared to low molecular weight heparin.
Timeline
- Start
- 2021-07-31
- Primary completion
- 2022-12-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ticagrelor | Small molecule | 2 mg/kg | Oral |
| Subject | Ticagrelor | Small molecule | 3 mg/kg | Oral |
Indications
No indication recorded.